Conavi Medical Grants Stock Options and Adjusts Audit Committee

Conavi Medical ( (TSE:CNVI) ) has issued an update.

Conavi Medical announced the approval of stock options for its directors, officers, employees, and consultants, totaling 5,849,098 options, exercisable at $0.39 CAD per share for ten years. This move is part of their Omnibus Equity Incentive Plan and reflects the company’s strategy to align interests with stakeholders. Additionally, there were minor changes in the Audit Committee’s composition, with Aaron Davidson stepping down and independent directors continuing to serve, indicating a focus on governance and operational adjustments.

More about Conavi Medical

Conavi Medical is a company focused on the design, manufacture, and marketing of imaging technologies for minimally invasive cardiovascular procedures. Its flagship product, the Novasight Hybrid™ System, integrates intravascular ultrasound and optical coherence tomography for enhanced coronary artery imaging, and has received regulatory approvals in the U.S., Canada, China, and Japan.

Average Trading Volume: 49,331

Technical Sentiment Signal: Sell

Current Market Cap: C$8.17M

For detailed information about CNVI stock, go to TipRanks’ Stock Analysis page.